[go: up one dir, main page]

IN185276B - - Google Patents

Info

Publication number
IN185276B
IN185276B IN1579DE1996A IN185276B IN 185276 B IN185276 B IN 185276B IN 1579DE1996 A IN1579DE1996 A IN 1579DE1996A IN 185276 B IN185276 B IN 185276B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Min Lin
Dieter Schweiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN185276(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IN185276B publication Critical patent/IN185276B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
IN1579DE1996 1995-07-17 1996-07-16 IN185276B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17

Publications (1)

Publication Number Publication Date
IN185276B true IN185276B (de) 2000-12-16

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1579DE1996 IN185276B (de) 1995-07-17 1996-07-16

Country Status (38)

Country Link
US (1) US6274740B1 (de)
EP (1) EP0839132B1 (de)
JP (1) JP4064459B2 (de)
KR (1) KR100400805B1 (de)
CN (1) CN1087289C (de)
AR (1) AR002849A1 (de)
AT (1) ATE199542T1 (de)
AU (1) AU700794B2 (de)
BG (1) BG63631B1 (de)
BR (1) BR9609714A (de)
CA (1) CA2220455C (de)
CO (1) CO4700441A1 (de)
CZ (1) CZ289421B6 (de)
DE (1) DE69611999T2 (de)
DK (1) DK0839132T5 (de)
EA (1) EA000625B1 (de)
EE (1) EE03605B1 (de)
ES (1) ES2156997T3 (de)
GE (1) GEP20002027B (de)
GR (1) GR3035859T3 (de)
HK (1) HK1018054A1 (de)
HR (1) HRP960312B1 (de)
HU (1) HU220343B (de)
IL (1) IL122161A (de)
IN (1) IN185276B (de)
MX (1) MX9708959A (de)
NO (1) NO309322B1 (de)
NZ (1) NZ313008A (de)
PE (1) PE1698A1 (de)
PL (1) PL191017B1 (de)
PT (1) PT839132E (de)
RO (1) RO120069B1 (de)
SI (1) SI0839132T1 (de)
SK (1) SK283204B6 (de)
UA (1) UA50743C2 (de)
UY (1) UY24286A1 (de)
WO (1) WO1997003960A1 (de)
ZA (1) ZA966043B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN1273449C (zh) 2000-12-27 2006-09-06 特瓦制药工业有限公司 阿伐他汀的晶型
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (de) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
SK16002003A3 (sk) * 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ES2338530T3 (es) * 2002-03-18 2010-05-10 Biocon Limited Inhibidores de hmg-coa reductasa amorfos del tamaño de particulas deseado.
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
WO2004089895A1 (en) * 2003-04-11 2004-10-21 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
DK1631533T3 (da) 2003-04-22 2009-06-02 Biocon Ltd Hidtil ukendt fremgangsmåde til stereoselektiv reduktion af beta-ketoestre
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US7557238B2 (en) 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
AU2004317570B2 (en) * 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CA2564030C (en) 2004-05-05 2010-06-08 Pfizer Products Inc. Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
RU2412191C2 (ru) * 2004-07-16 2011-02-20 Лек Фармасьютиклз Д.Д. Продукты окислительной деструкции кальций аторвастатина
WO2006021969A1 (en) 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
CA2582449A1 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
TW200630335A (en) * 2004-10-18 2006-09-01 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
EP1807055A1 (de) * 2004-10-28 2007-07-18 Warner-Lambert Company LLC Verfahren zur herstellung von amorphem atorvastatin
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
KR20070116963A (ko) * 2006-03-01 2007-12-11 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미 칼슘 결정형의 제조 방법
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
EP2185527A2 (de) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Neues polymorph von atorvastatin-calcium und seine verwendung zur herstellung von amorphem atorvastatin-calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (de) 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (de) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte.
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
AU725424B2 (en) 1995-07-17 2000-10-12 Warner-Lambert Company Crystalline (R-(R*,R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5- (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H- pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)

Also Published As

Publication number Publication date
NO309322B1 (no) 2001-01-15
BG63631B1 (bg) 2002-07-31
HK1018054A1 (en) 1999-12-10
US6274740B1 (en) 2001-08-14
EE9700369A (et) 1998-06-15
IL122161A (en) 1999-07-14
DE69611999T2 (de) 2001-07-26
GR3035859T3 (en) 2001-08-31
SI0839132T1 (de) 2001-06-30
CZ289421B6 (cs) 2002-01-16
CN1087289C (zh) 2002-07-10
PT839132E (pt) 2001-06-29
HUP9903017A3 (en) 2001-01-29
HRP960312A2 (en) 1998-02-28
CA2220455A1 (en) 1997-02-06
RO120069B1 (ro) 2005-08-30
PL191017B1 (pl) 2006-03-31
CO4700441A1 (es) 1998-12-29
MX9708959A (es) 1998-03-31
BG102188A (en) 1998-08-31
NO980209L (no) 1998-01-16
AU6497896A (en) 1997-02-18
KR19990029045A (ko) 1999-04-15
EA000625B1 (ru) 1999-12-29
NO980209D0 (no) 1998-01-16
IL122161A0 (en) 1998-04-05
PE1698A1 (es) 1998-02-19
KR100400805B1 (ko) 2003-12-24
JP4064459B2 (ja) 2008-03-19
UA50743C2 (uk) 2002-11-15
EP0839132B1 (de) 2001-03-07
AR002849A1 (es) 1998-04-29
EA199800128A1 (ru) 1998-08-27
ATE199542T1 (de) 2001-03-15
NZ313008A (en) 2000-01-28
WO1997003960A1 (en) 1997-02-06
SK283204B6 (sk) 2003-03-04
EP0839132A1 (de) 1998-05-06
ZA966043B (en) 1997-02-03
AU700794B2 (en) 1999-01-14
CZ12298A3 (cs) 1998-12-16
EE03605B1 (et) 2002-02-15
PL324463A1 (en) 1998-05-25
DE69611999D1 (de) 2001-04-12
JPH11510486A (ja) 1999-09-14
SK5898A3 (en) 1998-08-05
GEP20002027B (en) 2000-04-10
UY24286A1 (es) 1997-01-17
HU220343B (hu) 2001-12-28
CN1190956A (zh) 1998-08-19
DK0839132T5 (da) 2006-03-20
BR9609714A (pt) 1999-02-23
HRP960312B1 (en) 2001-10-31
ES2156997T3 (es) 2001-08-01
CA2220455C (en) 2002-09-24
DK0839132T3 (da) 2001-04-09

Similar Documents

Publication Publication Date Title
DE69638352D1 (de)
DE69637714D1 (de)
BR122012014331A2 (de)
BRPI9612258B1 (de)
BRPI9612138B1 (de)
DK143195A (de)
CH0741373H1 (de)
DK0727898T3 (de)
BR7501503U (de)
BR7502120U (de)
DK126096A (de)
CN3032568S (de)
CN3034473S (de)
CN3030489S (de)
CN3030542S (de)
CN3030543S (de)
CN3031001S (de)
CN3031350S (de)
CN3031655S (de)
CN3031742S (de)
CN3031926S (de)
CN3032332S (de)
CN3032390S (de)
CN3032522S (de)
CN3030296S (de)